Esperion Therapeutics’ (ESPR) Buy Rating Reiterated at HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $16.00 price objective on the biopharmaceutical company’s stock.

A number of other research firms also recently commented on ESPR. StockNews.com downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. JMP Securities reiterated a “market outperform” rating and issued a $7.00 target price on shares of Esperion Therapeutics in a research report on Thursday, January 23rd. Cantor Fitzgerald initiated coverage on Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of Esperion Therapeutics in a research note on Friday, December 13th. Finally, The Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a research note on Wednesday, December 18th. They set a “neutral” rating and a $4.00 target price for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $7.25.

Esperion Therapeutics Price Performance

NASDAQ ESPR opened at $1.86 on Tuesday. The company has a market capitalization of $366.49 million, a price-to-earnings ratio of -2.91 and a beta of 1.01. Esperion Therapeutics has a 12 month low of $1.58 and a 12 month high of $3.94. The company’s fifty day moving average price is $2.33 and its two-hundred day moving average price is $2.13.

Hedge Funds Weigh In On Esperion Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Traphagen Investment Advisors LLC bought a new stake in Esperion Therapeutics in the 3rd quarter valued at about $27,000. Cibc World Markets Corp acquired a new stake in shares of Esperion Therapeutics in the fourth quarter valued at approximately $39,000. Versor Investments LP bought a new stake in shares of Esperion Therapeutics during the third quarter valued at approximately $44,000. SJS Investment Consulting Inc. acquired a new position in shares of Esperion Therapeutics during the fourth quarter worth approximately $55,000. Finally, Boomfish Wealth Group LLC grew its holdings in Esperion Therapeutics by 17.1% in the 3rd quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock worth $58,000 after buying an additional 5,102 shares in the last quarter. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.